S1. Additional figures
Hep-G2 NIH3T3 Figure S7 . Cell viability of Hep-G2 (human hepatoma) and NIH3T3 (mouse embryonic fibroblast) after treatment with increasing HXL2 mixed with CD-AuNP (10 nM).
S2. Experimental section
General. All purchased chemicals and reagents are of analytical grade. Hydrogen tetrachloroaurate (III) hydrate (HAuCl 4 ·XH 2 O, 99.9%-Au) was purchased from J&K Chemical. Sodium citrate was obtained from J&K Chemical. Mercapto-β-cyclodextrin (β-CD-SH) was purchased from Shandong Zhiyuan Bio-technology Ltd (China). Proteins were purchased from Sigma-Aldrich. 1 H NMR and 13 C NMR spectra were recorded on a Bruker AM 400 MHz spectrometer with tetramethylsilane (TMS) as internal reference. Absorption spectra were measured on a Varian Cary 500 UV-Vis spectraphotometer. High resolution mass spectra (HRMS) were recorded with a Waters Micromass LCT mass spectrometer. Transmission electron microscopy (TEM) images were obtained on a JEOL 100CX transmission electron microscope operating at an accelerating bias voltage of 100 kV. Dynamic light scattering (DLS) was carried out on a Horiba LB-550 Dynamic Light Scattering Nano-Analyzer.
High Performance Liquid Chromatography (HPLC) was measured on a Shimadzu Prominence Series equipment.
Preparation of nanocomposites.
To prepare the nanocomposites, a solvent displacement method was carried out using water and dimethylsulfoxide. A dimethylsulfoxide solution of HXLs (1.5 µM) and an aqueous solution of mono-6-thiol-β-CD capped AuNP (7 nM) prepared according to a previous report 1 were mixed and stirred vigorously. HXL molecules with an adamantine tail could be entrapped to the hydrophobic cavity of CD due to hydrophobic interactions. The mixture was then centrifuged at 8000 rpm for 20 min to remove residual HXL molecules. Then, the HXL@CD-AuNP solution was further washed with Tris-HCl buffer (0.01 M, pH 7.4) and centrifuged. This step was repeated three times. The hydrocamptothecin (HCPT)-nanocomposite drug delivering system was prepared by the same protocol. 9, 75.9, 73.9, 73.6, 73.5, 72.4, 70.6, 69.8, 54.1, 18. 8, 136.0, 130.8, 130.3, 129.3, 128.1, 127.4(2), 127.2, 126.5, 126.1, 124.9, 124.7, 124.2, 124.1, 123.3, 72.9, 36.3(3), 33.1, 32.7, 31.9, 27.3(4) Synthesis of e1 (Scheme S2) (e2 5 and e3 6 were prepared according to previous protocols). To a soln. of e3 (408.7 mg, 1.31 mmol) in CH 2 Cl 2 were added e2 (193.9 mg, 1.31 mmol) and ethylene glycol monomethyl ether (6 mL). The resulting mixture was stirred at room temperature for 5 h. 162.9, 161.9, 150.8, 134.3, 130.8, 129.3, 128.9, 127.7, 127.1, 124.3, 124.2, 121.4, 120.1, 119.1, 109.6, 107.1, 103.9, 79.8, 72.4, 69.7, 69.5, 69.1, 68.1, 49.9, 42.7, 41.9, 38.2, 36.4, 36.3, 32.1, 28.6, 27.9 
